AVVA has been awarded with a Eurostars funded research programme by the European Commission under Horizon 2020. The award has been received for the research and development of an innovative product for the treatment of H. Pylori infection, Lactomezole.

AVVA Pharmaceuticals Ltd announces the first two EU file submissions for Lactofiltrum and Filtrum.

Filtrum and Lactofiltrum are the first in class lignin based products to be submitted to EU medical device competent authorities.

AVVA Pharmaceuticals Ltd announces participation at the CPhI Worldwide 2015 conference in Madrid, Spain.

For partnering opportunities please visit us at stand 10F49NEP, Hall 10.

AVVA Pharmaceuticals Ltd announces a new phase III clinical trial plan for Ecoclav.

Ecoclav belongs to a new class of antibiotics that address common medical needs, and concerns that to date were thought to be acceptable.  The project focuses on the development of a friendlier antibiotic, in respect to the human microecology and its impact on metabolic processes and the immune system.

Ecoclav is the analog of the commonly referred antibiotic Co-amoxiclav, a broad-spectrum antibiotic consisting of a b-lactam antibiotic and a b-lactamase inhibitor.

The broad use and importance of this medication is evident from its inclusion in the World health Organization’s (WHO) list of Essential Medicines. Co-Amoxiclav is the number one (1) used antibiotic worldwide.